# Stoke Therapeutics, Inc.: financial statements, quarterly

STOK · Nasdaq · CIK 1623526 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/stok.md) · [Financials](/companies/stok/financials.md) · [Filings](/companies/stok/filings.md) · [Insiders](/companies/stok/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/stok/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [3.3](/filings/0000950170-24-121445.md) | [2.8 d](/filings/0000950170-25-041170.md) | [4.2](/filings/0000950170-25-070296.md) | [4.8](/filings/0000950170-25-107332.md) | [4.9](/filings/0001193125-25-264720.md) | [22.6 d](/filings/0001193125-26-108362.md) | [159](/filings/0001193125-26-211874.md) | [13.8](/filings/0001193125-26-330557.md) | [10.6](/filings/0001193125-25-264720.md) | [1.4 d](/filings/0001193125-26-108362.md) | [6.2](/filings/0001193125-26-211874.md) | [9.3](/filings/0001193125-26-330557.md) |
| Research and development | $m | [20.3](/filings/0000950170-24-121445.md) | [21.8 d](/filings/0000950170-25-041170.md) | [22.4](/filings/0000950170-25-070296.md) | [21.1](/filings/0000950170-25-107332.md) | [22.2](/filings/0001193125-25-264720.md) | [23.4 d](/filings/0001193125-26-108362.md) | [32.7](/filings/0001193125-26-211874.md) | [25.9](/filings/0001193125-26-330557.md) | [37.7](/filings/0001193125-25-264720.md) | [41.7 d](/filings/0001193125-26-108362.md) | [39.7](/filings/0001193125-26-211874.md) | [49.5](/filings/0001193125-26-330557.md) |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | [12.7](/filings/0001193125-25-264720.md) | [12.8 d](/filings/0001193125-26-108362.md) | [14.7](/filings/0001193125-26-211874.md) | [15.3](/filings/0001193125-26-330557.md) | [16.0](/filings/0001193125-25-264720.md) | [21.1 d](/filings/0001193125-26-108362.md) | [20.0](/filings/0001193125-26-211874.md) | [25.3](/filings/0001193125-26-330557.md) |
| Operating income | $m | [(27.2)](/filings/0000950170-24-121445.md) | [(29.6) d](/filings/0000950170-25-041170.md) | [(28.4)](/filings/0000950170-25-070296.md) | [(29.3)](/filings/0000950170-25-107332.md) | [(30.0)](/filings/0001193125-25-264720.md) | [(13.7) d](/filings/0001193125-26-108362.md) | [111](/filings/0001193125-26-211874.md) | [(27.3)](/filings/0001193125-26-330557.md) | [(43.1)](/filings/0001193125-25-264720.md) | [(61.4) d](/filings/0001193125-26-108362.md) | [(53.4)](/filings/0001193125-26-211874.md) | [(65.4)](/filings/0001193125-26-330557.md) |
| Interest expense | $m | not reported | not reported | [0.0](/filings/0000950170-25-070296.md) | [0.0](/filings/0000950170-25-107332.md) | [0.0](/filings/0001193125-25-264720.md) | [(0.0) d](/filings/0001193125-26-108362.md) | [0.0](/filings/0001193125-26-211874.md) | [0.0](/filings/0001193125-26-330557.md) | [0.0](/filings/0001193125-25-264720.md) | [0.0 d](/filings/0001193125-26-108362.md) | [0.0](/filings/0001193125-26-211874.md) | [0.0](/filings/0001193125-26-330557.md) |
| Income tax | $m | [0.0](/filings/0000950170-24-121445.md) | not reported | [0.0](/filings/0000950170-25-070296.md) | [0.0](/filings/0000950170-25-107332.md) | [0.0](/filings/0001193125-25-264720.md) | not reported | [1.3](/filings/0001193125-26-211874.md) | [0.0](/filings/0001193125-26-330557.md) | [(1.3)](/filings/0001193125-25-264720.md) | [0.0 d](/filings/0001193125-26-108362.md) | [0.0](/filings/0001193125-26-211874.md) | [0.0](/filings/0001193125-26-330557.md) |
| Net income | $m | [(24.5)](/filings/0000950170-24-121445.md) | [(27.0) d](/filings/0000950170-25-041170.md) | [(26.4)](/filings/0001193125-25-264720.md) | [(25.7)](/filings/0001193125-25-264720.md) | [(26.4)](/filings/0001193125-25-264720.md) | [(10.5) d](/filings/0001193125-26-108362.md) | [113](/filings/0001193125-26-330557.md) | [(23.5)](/filings/0001193125-26-330557.md) | [(38.3)](/filings/0001193125-25-264720.md) | [(57.9) d](/filings/0001193125-26-108362.md) | [(50.0)](/filings/0001193125-26-330557.md) | [(61.6)](/filings/0001193125-26-330557.md) |
| Diluted EPS | $ per share | [(0.55)](/filings/0000950170-24-121445.md) | not reported | [(0.57)](/filings/0000950170-25-070296.md) | [(0.46)](/filings/0000950170-25-107332.md) | [(0.47)](/filings/0001193125-25-264720.md) | not reported | [1.90](/filings/0001193125-26-211874.md) | [(0.40)](/filings/0001193125-26-330557.md) | [(0.65)](/filings/0001193125-25-264720.md) | not reported | [(0.79)](/filings/0001193125-26-211874.md) | [(0.93)](/filings/0001193125-26-330557.md) |
| Basic EPS | $ per share | [(0.55)](/filings/0000950170-24-121445.md) | not reported | [(0.57)](/filings/0000950170-25-070296.md) | [(0.46)](/filings/0000950170-25-107332.md) | [(0.47)](/filings/0001193125-25-264720.md) | not reported | [1.95](/filings/0001193125-26-211874.md) | [(0.40)](/filings/0001193125-26-330557.md) | [(0.65)](/filings/0001193125-25-264720.md) | not reported | [(0.79)](/filings/0001193125-26-211874.md) | [(0.93)](/filings/0001193125-26-330557.md) |

- Revenue: us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [190](/filings/0000950170-24-121445.md) | [191](/filings/0000950170-25-041170.md) | [179](/filings/0000950170-25-070296.md) | [193](/filings/0000950170-25-107332.md) | [150](/filings/0001193125-25-264720.md) | [128](/filings/0001193125-26-108362.md) | [275](/filings/0001193125-26-211874.md) | [101](/filings/0001193125-26-330557.md) | [83.4](/filings/0001193125-25-264720.md) | [84.2](/filings/0001193125-26-330557.md) | [156](/filings/0001193125-26-211874.md) | [110](/filings/0001193125-26-330557.md) |
| Current assets | $m | [230](/filings/0000950170-23-060224.md) | [215](/filings/0000950170-25-041170.md) | [193](/filings/0000950170-24-053535.md) | [297](/filings/0000950170-24-092738.md) | [254](/filings/0000950170-24-121445.md) | [233](/filings/0001193125-26-108362.md) | [376](/filings/0000950170-25-070296.md) | [270](/filings/0000950170-25-107332.md) | [272](/filings/0001193125-25-264720.md) | [306](/filings/0001193125-26-330557.md) | [367](/filings/0001193125-26-211874.md) | [323](/filings/0001193125-26-330557.md) |
| Total assets | $m | [240](/filings/0000950170-23-060224.md) | [228](/filings/0000950170-25-041170.md) | [205](/filings/0000950170-24-053535.md) | [308](/filings/0000950170-24-092738.md) | [293](/filings/0000950170-24-121445.md) | [272](/filings/0001193125-26-108362.md) | [407](/filings/0000950170-25-070296.md) | [385](/filings/0000950170-25-107332.md) | [360](/filings/0001193125-25-264720.md) | [418](/filings/0001193125-26-330557.md) | [443](/filings/0001193125-26-211874.md) | [394](/filings/0001193125-26-330557.md) |
| Current liabilities | $m | [25.2](/filings/0000950170-23-060224.md) | [30.8](/filings/0000950170-25-041170.md) | [35.6](/filings/0000950170-24-053535.md) | [44.5](/filings/0000950170-24-092738.md) | [49.9](/filings/0000950170-24-121445.md) | [40.1](/filings/0001193125-26-108362.md) | [44.7](/filings/0000950170-25-070296.md) | [38.7](/filings/0000950170-25-107332.md) | [41.7](/filings/0001193125-25-264720.md) | [57.9](/filings/0001193125-26-330557.md) | [40.8](/filings/0001193125-26-211874.md) | [41.9](/filings/0001193125-26-330557.md) |
| Total liabilities | $m | [66.9](/filings/0000950170-23-060224.md) | [68.8](/filings/0000950170-25-041170.md) | [64.8](/filings/0000950170-24-053535.md) | [65.0](/filings/0000950170-24-092738.md) | [61.2](/filings/0000950170-24-121445.md) | [42.5](/filings/0001193125-26-108362.md) | [56.8](/filings/0000950170-25-070296.md) | [49.6](/filings/0000950170-25-107332.md) | [52.2](/filings/0001193125-25-264720.md) | [66.0](/filings/0001193125-26-330557.md) | [48.4](/filings/0001193125-26-211874.md) | [48.4](/filings/0001193125-26-330557.md) |
| Shareholders' equity | $m | [173](/filings/0000950170-24-121445.md) | [160](/filings/0001193125-26-108362.md) | [140](/filings/0001193125-25-264720.md) | [243](/filings/0001193125-25-264720.md) | [232](/filings/0001193125-25-264720.md) | [229](/filings/0001193125-26-330557.md) | [350](/filings/0001193125-26-330557.md) | [335](/filings/0001193125-26-330557.md) | [308](/filings/0001193125-25-264720.md) | [352](/filings/0001193125-26-330557.md) | [395](/filings/0001193125-26-330557.md) | [346](/filings/0001193125-26-330557.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(17.3) d](/filings/0000950170-24-121445.md) | [(20.6) d](/filings/0000950170-25-041170.md) | [(24.6)](/filings/0000950170-25-070296.md) | [(17.5) d](/filings/0000950170-25-107332.md) | [(21.6) d](/filings/0001193125-25-264720.md) | [(23.2) d](/filings/0001193125-26-108362.md) | [132](/filings/0001193125-26-211874.md) | [(25.4) d](/filings/0001193125-26-330557.md) | [(30.4) d](/filings/0001193125-25-264720.md) | [(30.5) d](/filings/0001193125-26-108362.md) | [(60.6)](/filings/0001193125-26-211874.md) | [(56.6) d](/filings/0001193125-26-330557.md) |
| Capital expenditure | $m | [0.4 d](/filings/0000950170-24-121445.md) | [0.2 d](/filings/0000950170-25-041170.md) | [0.0](/filings/0000950170-25-070296.md) | [0.0 d](/filings/0000950170-25-107332.md) | [0.1 d](/filings/0001193125-25-264720.md) | [0.0 d](/filings/0001193125-26-108362.md) | [0.2](/filings/0001193125-26-211874.md) | [0.2 d](/filings/0001193125-26-330557.md) | [0.1 d](/filings/0001193125-25-264720.md) | [0.2 d](/filings/0001193125-26-108362.md) | [0.4](/filings/0001193125-26-211874.md) | [2.0 d](/filings/0001193125-26-330557.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [39.4](/filings/0000950170-23-060224.md) | [42.5](/filings/0000950170-24-053535.md) | [44.2](/filings/0000950170-24-092738.md) | [44.3](/filings/0000950170-24-121445.md) | [46.2](/filings/0000950170-25-070296.md) | [55.8](/filings/0000950170-25-107332.md) | [56.3](/filings/0001193125-25-264720.md) | [59.4](/filings/0001193125-26-211874.md) | [58.4](/filings/0001193125-26-330557.md) | [58.6](/filings/0001193125-25-264720.md) | [63.1](/filings/0001193125-26-211874.md) | [66.0](/filings/0001193125-26-330557.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 64,526,242 at 2026-07-30, from the cover of the [10-Q filed 2026-08-03](/filings/0001193125-26-330557.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.